1.Systemic Therapy Plus Thermal Ablation Versus Systemic Therapy Alone For Oligometastatic Liver Metastases From Non-Small Cell Lung Cancer 2.Silver Nanoparticles Covered Metallic Stent To Prevent Stent-Induced Tissue Hyperplasia After Stent Placement In

Purpose:Non-small cell lung cancer(NSCLC)patients with liver metastases(LMs)tend to possess a poor prognosis.Systemic therapy(chemotherapy and targeted therapy)is the main treatment for advanced lung cancer,however mounting evidence has shown that systemic therapy plus local therapy(surgical or radiotherapy)can prolong the progression-free survival(PFS)and improve the prognosis of patients with oligometastases from malignant diseases.Nevertheless,thermal ablation is rarely reported or studied in oligometastatic NSCLC patients.This study assessed and compared the efficacy and long-term outcomes of systemic therapy plus thermal ablation(group A)versus systemic therapy alone(group B)for oligometastatic LMs from NSCLC.Materials and Methods:From November 2012 to December 2017,total 61 patients(mean age,59.0 years;35 males)with oligometastatic LMs from NSCLC(≤5 metastatic lesions)who received systemic therapy with(n=21,group A)or without(n=40,group B)thermal ablation were analyzed.PFS and overall survival(OS)were estimated by Kaplan-Meier curves and tested with Log-rank method.Univariate and multivariate analyses were performed with Cox regression method.This was a retrospective study approved by the institutional review board of National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences.Written informed consent was waived due to the retrospective design.Results:The demographic and clinical characteristics were not significantly different between the groups(all P ≥ 0.05).In total,28 LMs were entirely ablated,rendering a technical success rate of 100%,without major complications.The overall 6-month response rate was significantly higher in group A than group B[57.1%(12/21)vs.26.3%(10/38);P=.026].The median PFS in group A was significantly longer than in group B[11.0(95%CI,7.9-16.2)months vs.5.2(95%CI,3.7-7.9)months;P=.001].However,the median OS was not significantly different[27.7(95%CI,20.6-44.4)months vs.17.7(95%CI,14.5-27.5)months;P=.152].Conclusion:Systemic therapy plus thermal ablation may prolong PFS but not OS in oligometastatic LMs from NSCLC.